With Panel Advice In, FDA To Conclude Menaflex 510(k) Re-Review In Weeks

FDA will announce the outcome of its re-review of ReGen Biologic's 510(k)-cleared Menaflex knee repair device "in the coming weeks," CDRH Director Jeffrey Shuren said last week

More from Archive

More from Medtech Insight